News Archive
July 2022
RZNOMICS advance its lead compound, a gene therapy produced using CEVEC's CAP® Ad Technology, into clinical development
CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients